Bifunctional

Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update

Retrieved on: 
Wednesday, February 14, 2024
IPR, Research, CMO, Decompression (diving), PR, Society, Bifunctional, MNP, PRS, Bank statement, Melanoma, OTCQB, ICI, Toronto Stock Exchange, SITC, CBV, Annual general meeting, European Medicines Agency, Partnership, BTD, Highlight, AACR, Conference, Safety, Clinical trial, Survival, Neurology, CFO, EMA, Enzyme, MD, ECA, FDA, TSX, Cancer, EDGAR, Pembrolizumab, Response, MDNA, SNO, Patient, Pharmaceutical industry

Today, the Company reports promising clinical data from the on-going monotherapy escalation and expansion arms of the ABILITY-1 study.

Key Points: 
  • Today, the Company reports promising clinical data from the on-going monotherapy escalation and expansion arms of the ABILITY-1 study.
  • Clinical update from the combination arm of the ABILITY-1 study evaluating MDNA11 in with KEYTRUDA® expected in H1 and H2 of 2024.
  • Research and development expenses of $3.0 million were incurred during the quarter ended December 31, 2023, compared with $2.9 million incurred in the quarter ended December 31, 2022.
  • General and administrative expenses of $1.8 million were incurred during the quarter ended December 31, 2023, compared with $2.0 million during the quarter ended December 31, 2022.

Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights

Retrieved on: 
Tuesday, November 14, 2023
Doctor of Philosophy, Bispecific monoclonal antibody, Pancreatic cancer, MSI, Brain, Research, Annual general meeting, Glioblastoma, Metalloproteinase, Toronto Stock Exchange, Patient, MDNA, Pakistan Society of Neuro-Oncology, Intellectual property, Pembrolizumab, OTC Markets Group, Neuro-Oncology (journal), Conference, Standard of care, Melanoma, SITC, Survival, Partnership, Cancer, Neoplasm, Bifunctional, TSX, SNO, Microsatellite instability, Decompression (diving), Society, MMR, Patent, Pharmaceutical industry, Cryptocurrency, Immunotherapy

TORONTO and HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA; OTC: MDNAF), a clinical-stage company focused on the design and development of novel evolutionary superkines to create revolutionary immunotherapies, today announced financial results and corporate highlights for the second quarter of fiscal 2024, ended September 30, 2023.

Key Points: 
  • We look forward to reporting initial Phase 2 dose expansion data from both the monotherapy and combination arms during the first half of 2024,” concluded Dr.
  • Clinical update from the ABILITY study’s MDNA11 plus pembrolizumab Phase 2 combination arm expected in the first half of 2024.
  • Research and development expenses of $3.1 million were incurred during the quarter ended September 30, 2023, compared with $2.4 million incurred in the quarter ended September 30, 2022.
  • General and administrative expenses of $2.3 million were incurred during the quarter ended September 30, 2023, compared with $2.4 million during the quarter ended September 30, 2022.

Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Retrieved on: 
Tuesday, October 3, 2023
Stimulator of interferon genes, Bifunctional, AACR, Biskit, Syngenic, Survival, Immunotherapy, MDNA, CD8, Synergism, TSX, Neoplasm, Poster, PD-1, IL-2R, Conference, Pharmaceutical industry, Vaccine

TORONTO and HOUSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced that new preclinical data characterizing MDNA223, an anti-PD1-IL-2 BiSKIT (Bifunctional SuperKine for ImmunoTherapy), were presented at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy held from October 1 - 4, 2023, in Toronto, Canada.

Key Points: 
  • TORONTO and HOUSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced that new preclinical data characterizing MDNA223, an anti-PD1-IL-2 BiSKIT (Bifunctional SuperKine for ImmunoTherapy), were presented at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy held from October 1 - 4, 2023, in Toronto, Canada.
  • “We believe that our dual-functioning BiSKIT candidates, such as MDNA223, are more potent and selective and may have an increased capacity to induce superior CD8+ T cell responses against tumor cells.
  • The sum of encouraging preclinical data on MDNA223 highlights the potential of Medicenna’s BiSKIT platform to broadly delivery effective therapy to otherwise challenging-to-treat ‘cold’ tumors.
  • Copies of the poster will be posted to the “ Events and Presentations ” page of Medicenna’s website following the conclusion of the meeting.

Medicenna Strengthens IP Portfolio with U.S. Patent Granted for the Use of Interleukin-2 Superkine Fusion Proteins in Oncology

Retrieved on: 
Tuesday, August 1, 2023
1836 U.S. Patent Office fire, Bifunctional, Mitochondrion, Survival, Cancer, NK, MDNA, Multiple sclerosis, Patent, Health, Immunotherapy, Muscular dystrophy, Bcl-xL, Vaccine, Pharmaceutical industry

TORONTO and HOUSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the issuance of U.S. Patent No.

Key Points: 
  • TORONTO and HOUSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the issuance of U.S. Patent No.
  • The patent further strengthens Medicenna's intellectual property around its BiSKIT™ (Bifunctional SuperKine for ImmunoTherapy) platform.
  • The patent protects a new method for enhancing fitness, survival and proliferation of cancer killing effector T cells and NK cells.
  • The Company’s Superkine patent estate is currently comprised of 56 granted and 61 pending patent applications.

Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting

Retrieved on: 
Monday, April 17, 2023
Orange County Convention Center, Bifunctional, AACR, PE, CD3, ICE, Neoplasm, CD122, Cancer, Tumor microenvironment, NK, Toxicity, MDNA, Patient, TME, Poster, Immunotherapy, FC, Interleukin, Vaccine, Pharmaceutical industry

TORONTO and HOUSTON, April 17, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that new preclinical data characterizing the Interleukin 13 (IL-13) Superkines, MDNA132 and MDNA213, and a series of next generation IL-13 Superkine therapies, were presented at the 2023 Annual Meeting of the American Association for Cancer Research (AACR), which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 - 19, 2023.

Key Points: 
  • “Tumors that express high levels of IL-13Rα2 are known to be aggressive, resulting in poor survival outcomes for cancer patients.
  • MDNA19-MDNA213: A first-in-class BiSKIT™ (Bifunctional SuperKines for ImmunoTherapy) comprised of MDNA213 fused to MDNA19, the Fc version of our IL-2 Superkine MDNA11.
  • In vitro data demonstrate that this molecule exhibits selective and potent cytotoxic activity towards human and murine cancer cells that express IL-13Rα2.
  • It will be available on the Events and Presentations page of Medicenna’s website following the conclusion of the meeting.

Medicenna Announces Upcoming Presentation at the AACR Annual Meeting

Retrieved on: 
Wednesday, March 15, 2023
Poster, Tumor microenvironment, AACR, MDNA, Prostate, Annual general meeting, Bifunctional, American Association for Cancer Research, Orange County Convention Center, Neoplasm, Breast, Pharmaceutical industry, Book

The full text of the published abstract can be found on the AACR Annual Meeting website.

Key Points: 
  • The full text of the published abstract can be found on the AACR Annual Meeting website.
  • The poster will describe preclinical studies characterizing a long-acting version of MDNA132 and BiSKITs™, (Bifunctional SuperKine ImmunoTherapies) comprising MDNA132 fused to an IL-2 super-agonist or anti-PD1 antibody.
  • MDNA132 is an IL-13 Superkine designed to enable targeted delivery of immunotherapies to the tumor microenvironment.
  • Following the conclusion of the AACR Meeting, a copy of the poster will be available on the “ Events and Presentations ” page of Medicenna’s website.

Medicenna Strengthens Intellectual Property Protection for MDNA11 and BiSKITs™ Programs with Issuance of U.S. Patent

Retrieved on: 
Thursday, January 5, 2023
Cancer, Pembrolizumab, CTLA4, IP, Patent, Biskit, Toxicity, Patient, MDNA, Immunotherapy, Intellectual property, Bifunctional, Cell, Pharmaceutical industry

TORONTO and HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,542,312 titled “IL-2 Superagonists in Combination with Anti-PD-1.” The patent provides intellectual property (IP) protection for methods of treating cancer with an IL-2 Superkine such as MDNA11 and a PD1 (for example, pembrolizumab), PDL1 or CTLA-4 checkpoint inhibitor in combination, as planned in the on-going ABILITY clinical trial, or as a single agent using our BiSKIT™ (Bifunctional SuperKine for ImmunoTherapy) platform. The patent’s term extends into at least 2039 without accounting for any potential extensions.

Key Points: 
  • The patent’s term extends into at least 2039 without accounting for any potential extensions.
  • MDNA223 is a preclinical-stage BiSKIT consisting of an anti-PD1 antibody linked to an IL-2 super-agonist (MDNA109FEAA).
  • Both MDNA11 and MDNA109FEAA are designed to selectively stimulate anti-cancer immune cells without activating cells associated with pro-tumor immune pathways or extreme toxicity.
  • This newly issued patent adds to Medicenna’s portfolio of issued and filed patents and applications providing protection for the Company’s innovative IL‐2 Superkines, including MDNA11, in the U.S., Europe, Japan, China, Canada, India, and Australia.

HCW Biologics Enters CRADA with National Cancer Institute

Retrieved on: 
Thursday, December 8, 2022
Laboratory, Molecular biology, MRC Laboratory of Molecular Biology, CCR, Adenocarcinoma, Pancreatic cancer, Degenerative disease, Inflammation, Bifunctional, Safety, CRADA, University of Minnesota, Cancer, Tissue, ClinicalTrials.gov, Cooperative research and development agreement, Masonic Cancer Center, Principal, Recurrence, Adenosquamous carcinoma, National Cancer Institute, Diabetes, Neurodegeneration, Internal medicine, Oncology, Survival, Research, NCI, IND, Disease, HCW, Death, University, Development, Patient, Drug resistance, Incidence, Pharmaceutical industry, Dietary supplement

MIRAMAR, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that under a Cooperative Research and Development Agreement (CRADA), the National Cancer Institute (NCI) and HCW Biologics Inc. (HCW Biologics) will collaborate to perform a Phase 1b/2 clinical study to evaluate the safety and tolerability of HCW Biologics’ proprietary agent, HCW9218, in patients with advanced/metastatic pancreatic cancer.

Key Points: 
  • MIRAMAR, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that under a Cooperative Research and Development Agreement (CRADA), the National Cancer Institute (NCI) and HCW Biologics Inc. (HCW Biologics) will collaborate to perform a Phase 1b/2 clinical study to evaluate the safety and tolerability of HCW Biologics’ proprietary agent, HCW9218, in patients with advanced/metastatic pancreatic cancer.
  • About the Center for Cancer Research at the National Cancer Institute:
    The Center for Cancer Research (CCR), NCI’s specialized internal cancer center, has a robust clinical research program, the largest at the National Institutes of Health.
  • Pancreatic cancer is the third leading cause of cancer death in the United States.
  • The invention of HCW Biologics’ two lead molecules, HCW9218 and HCW9302, was made via the TOBI™ discovery platform.

Medicenna Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 ABILITY Study of MDNA11 at the SITC Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
GLOBE, AES, Pharmacodynamics, Convention center, Forward-looking statement, Melanoma, Doctor of Philosophy, PK, Pancreatic cancer, Annual general meeting, Boston Convention and Exhibition Center, CD25, Immunotherapy, GBM, Eosinophil, Society for Immunotherapy of Cancer, Renal cell carcinoma, Annual report, NASDAQ, News, Bifunctional, Safety, SITC, Brain, CD122, EMA, Company, Pharmacokinetics, Pembrolizumab, NK, Patient, Time, CEO, Merck & Co., Society, MDNA, FDA, PD, Pharmaceutical industry, Online shopping, Interior design

TORONTO and HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced new safety, pharmacokinetic (PK), and pharmacodynamic (PD) data from the first four dose escalation cohorts of the Phase 1/2 ABILITY study of MDNA11, the Company’s “beta-only” long-acting IL-2 super-agonist. The data are featured in two posters being presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 – 12, 2022.

Key Points: 
  • As previously reported, data from the first four (low and mid) dose escalation cohorts of the ABILITY study show tumor control in five of fourteen evaluable patients treated with MDNA11 monotherapy administered intravenously once every two weeks.
  • The confirmatory scan for this patient showed further tumor reduction compared to prior scans, suggesting durable anti-cancer activity following MDNA11 monotherapy.
  • Initial anti-tumor activity from the fifth dose escalation cohort, alongside a broader update from all of the trials dose escalation cohorts, is expected in the first quarter of 2023.
  • The trial includes an MDNA11 monotherapy arm, as well as a combination arm designed to evaluate MDNA11 with KEYTRUDA (pembrolizumab).

Medicenna Reports Second Quarter Fiscal 2023 Financial Results and Operational Highlights

Retrieved on: 
Friday, November 4, 2022
MSD, Patient, EMA, FDA, Population, MD, United States patent law, Research, Cytokine, Annual report, Patent, Melanoma, SD, SITC, Company, CD122, GLOBE, Intellectual property, IND, NK, Toxic leukoencephalopathy, Immunotherapy, CEO, Renal cell carcinoma, Mission statement, Forward-looking statement, ID, PD, Society, Pharmacokinetics, EDGAR, Doctor of Philosophy, Method, 1836 U.S. Patent Office fire, MDNA, Annual general meeting, Biskit, Pancreatic cancer, International Cytokine & Interferon Society, Safety, GBM, CD25, Brain, Merck & Co., PR, USD, NASDAQ, IP, Pembrolizumab, United, News, SEDAR, GMP, Leukemia, Bifunctional, Mobile phone, Pharmaceutical industry, Vaccine, Security (finance), Cryptocurrency, Audit, Merck

TORONTO and HOUSTON, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended September 30, 2022. All dollar amounts are in Canadian currency unless otherwise noted.

Key Points: 
  • The confirmatory scan for this patient showed further tumor reduction compared to prior scans, suggesting durable anti-cancer activity following MDNA11 monotherapy.
  • All patients in the trials dose escalation phase are treated with MDNA11 monotherapy via intravenous infusion every two weeks.
  • Under the terms of the agreement, Medicenna will sponsor the study and Merck will supply KEYTRUDA.
  • Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated.